Patents by Inventor Jay P. Morgenstern
Jay P. Morgenstern has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190136284Abstract: The present disclosure provides nucleic acids encoding a Large ATP-binding regulator of the LuxR family (LAL) of transcription factors, vectors and host cells including such nucleic acids, and methods for producing compounds (e.g., polyketides or ?-lactam compounds) with such nucleic acids, vectors, and/or host cells.Type: ApplicationFiled: April 12, 2017Publication date: May 9, 2019Applicant: Warp Drive Bio, Inc.Inventors: Brian R. BOWMAN, Joshua A.V. BLODGETT, Gregory L. VERDINE, Daniel C. GRAY, Jay P. MORGENSTERN, Lucy FOULSTON, Keith ROBISON
-
Patent number: 10233217Abstract: Nucleotide sequences are disclosed that encode novel chimeric insecticidal proteins exhibiting Lepidopteran inhibitory activity. Particular embodiments provide compositions and transformed plants, plant parts, and seeds containing the recombinant nucleic acid molecules encoding one or more of the chimeric insecticidal proteins.Type: GrantFiled: October 15, 2015Date of Patent: March 19, 2019Assignee: Monsanto Technology LLCInventors: James A. Baum, Sara A. Salvador, Jinling Wang, Stanislaw Flasinski, Thomas A. Cerruti, Crystal L. Dart, Leigh H. English, Xiaoran Fu, Victor M. Guzov, Arlene R. Howe, Jay P. Morgenstern, James K. Roberts
-
Publication number: 20180208631Abstract: Disclosed herein are nucleotide sequences encoding an insecticidal protein exhibiting Lepidopteran inhibitory activity, as well as novel insecticidal proteins referred to herein as a BCW 001, BCW 002, BCW 003, and BCW toxic protein-containing chimeras and BCW toxin insecticide, transgenic plants expressing the chimeras or the insecticide, and methods for detecting the presence of the nucleotide sequences or the insecticide in a biological sample.Type: ApplicationFiled: January 11, 2018Publication date: July 26, 2018Inventors: James A. Baum, David J. Bowen, Catherine A. Chay, David J. Chi, William P. Clinton, Crystal L. Dart, Leigh English, Stanislaw Flasinski, Victor M. Guzov, Kevin A. Jarrell, Uma R. Kesanapalli, Thomas M. MaIvar, Robert M. McCarroll, Jason S. Milligan, Jay P. Morgenstern, Deborah G. Rucker, Sara A. Salvador, Temple F. Smith, Carlos E. Soto, Collin M. Stultz, Brian M. Turczyk, Ty T. Vaughn, Moritz W.F.F. Von Rechenberg
-
Publication number: 20180127772Abstract: Nucleotide sequences are disclosed that encode novel chimeric insecticidal proteins exhibiting Lepidopteran inhibitory activity. Particular embodiments provide compositions and transformed plants, plant parts, and seeds containing the recombinant nucleic acid molecules encoding one or more of the chimeric insecticidal proteins.Type: ApplicationFiled: December 20, 2017Publication date: May 10, 2018Applicant: Monsanto Technology LLCInventors: James A. Baum, Thomas A. Cerruti, Crystal L. Dart, Leigh H. English, Stanislaw Flasinski, Xiaoran Fu, Victor M. Guzov, Arlene R. Howe, Jay P. Morgenstern, James K. Roberts, Sara A. Salvador, Jinling Wang
-
Publication number: 20180127774Abstract: Nucleotide sequences are disclosed that encode novel chimeric insecticidal proteins exhibiting Lepidopteran inhibitory activity. Particular embodiments provide compositions and transformed plants, plant parts, and seeds containing the recombinant nucleic acid molecules encoding one or more of the chimeric insecticidal proteins.Type: ApplicationFiled: December 20, 2017Publication date: May 10, 2018Applicant: Monsanto Technology LLCInventors: James A. Baum, Thomas A. Cerruti, Crystal L. Dart, Leigh H. English, Stanislaw Flasinski, Xiaoran Fu, Victor M. Guzov, Arlene R. Howe, Jay P. Morgenstern, James K. Roberts, Sara A. Salvador, Jinling Wang
-
Publication number: 20180127773Abstract: Nucleotide sequences are disclosed that encode novel chimeric insecticidal proteins exhibiting Lepidopteran inhibitory activity. Particular embodiments provide compositions and transformed plants, plant parts, and seeds containing the recombinant nucleic acid molecules encoding one or more of the chimeric insecticidal proteins.Type: ApplicationFiled: December 20, 2017Publication date: May 10, 2018Applicant: Monsanto Technology LLCInventors: James A. Baum, Thomas A. Cerruti, Crystal L. Dart, Leigh H. English, Stanislaw Flasinski, Xiaoran Fu, Victor M. Guzov, Arlene R. Howe, Jay P. Morgenstern, James K. Roberts, Sara A. Salvador, Jinling Wang
-
Publication number: 20180127775Abstract: Nucleotide sequences are disclosed that encode novel chimeric insecticidal proteins exhibiting Lepidopteran inhibitory activity. Particular embodiments provide compositions and transformed plants, plant parts, and seeds containing the recombinant nucleic acid molecules encoding one or more of the chimeric insecticidal proteins.Type: ApplicationFiled: December 20, 2017Publication date: May 10, 2018Applicant: Monsanto Technology LLCInventors: James A. Baum, Thomas A. Cerruti, Crystal L. Dart, Leigh H. English, Stanislaw Flasinski, Xiaoran Fu, Victor M. Guzov, Arlene R. Howe, Jay P. Morgenstern, James K. Roberts, Sara A. Salvador, Jinling Wang
-
Publication number: 20170327547Abstract: Nucleotide sequences are disclosed that encode novel chimeric insecticidal proteins exhibiting Lepidopteran inhibitory activity. Particular embodiments provide compositions and transformed plants, plant parts, and seeds containing the recombinant nucleic acid molecules encoding one or more of the chimeric insecticidal proteins.Type: ApplicationFiled: July 21, 2017Publication date: November 16, 2017Applicant: Monsanto Technology LLCInventors: James A. BAUM, Thomas A. CERRUTI, Crystal L. DART, Leigh H. ENGLISH, Stanislaw FLASINSKI, Xiaoran FU, Victor M. GUZOV, Arlene R. HOWE, Jay P. MORGENSTERN, James K. ROBERTS, Sara A. SALVADOR, Jinling WANG
-
Publication number: 20160108428Abstract: Nucleotide sequences are disclosed that encode novel chimeric insecticidal proteins exhibiting Lepidopteran inhibitory activity. Particular embodiments provide compositions and transformed plants, plant parts, and seeds containing the recombinant nucleic acid molecules encoding one or more of the chimeric insecticidal proteins.Type: ApplicationFiled: October 15, 2015Publication date: April 21, 2016Applicant: MONSANTO TECHNOLOGY LLCInventors: James A. Baum, Thomas A. Cerruti, Crystal L. Dart, Leigh H. English, Xiaoran Fu, Victor M. Guzov, Arlene R. Howe, Jay P. Morgenstern, James K. Roberts, Sara A. Salvador, Jinling Wang
-
Patent number: 7666441Abstract: Isolated nucleic acids encoding allergens of Canis familiaris, Can f I or Can f II, are disclosed. A cDNA encoding a peptide having a Can f I activity and a predicted molecular weight of about 19,200 daltons is also described. A cDNA encoding a peptide having Can f II activity and a predicted molecular weight of about 18,200 daltons is also disclosed. The nucleic acids can be used as probes to detect the presence of Can f I or Can f II nucleic acid in a sample or for the recombinant production of petides having a Can f I or Can f II activity. Peptides having a Can f I or Can f II activity can be used in compositions suitable for pharmaceutical administration or methods of diagnosing sensitivity to dog dander.Type: GrantFiled: December 12, 2006Date of Patent: February 23, 2010Assignee: Merck Patent GmbHInventors: Jay P. Morgenstern, Christine Bizinkauskas, Andrzej Konieczny, Andrew W. Brauer
-
Patent number: 7482008Abstract: A substantially pure, covalently linked human T cell reactive feline protein (TRFP) has been isolated from vacuum bag extract obtained by affinity purification of house dust collected from several homes with cats; DNA encoding all or a portion of the TRFP or peptide; compositions containing such a protein or peptide or portions thereof; and antibodies reactive with the TRFP or peptide are disclosed. Also disclosed are recombinant TRFP or peptide; modified or mutated TRFP peptides; their use for diagnostic or therapeutic purposes.Type: GrantFiled: September 15, 2000Date of Patent: January 27, 2009Assignee: Merck Patent GmbHInventors: Malcolm L. Gefter, Richard D. Garman, Julia L. Greenstein, Mei-chang Kuo, Bruce L. Rogers, Irwin J. Griffith, Jay P. Morgenstern, Julian F. Bond, Andrew W. Brauer, Malcolm Morville, Thomas J. Briner, Ze'ev Shaked
-
Patent number: 7211408Abstract: The present invention provides peptides having T cell stimulating activity termed recombitope peptides. Recombitope peptides of the invention preferably comprise at least two T cell epitopes derived from the same or from different protein antigens, and more preferably comprise at least two regions, each region preferably having human T cell stimulating activity and each region comprising at least one T cell epitope derived from a protein antigen. Recombitope peptides of the invention can be derived from protein allergens, autoantigens, or other protein antigens. The invention also provides methods of diagnosing sensitivity to a protein allergen or other protein antigen in an individual, methods to treat such sensitivity and therapeutic compositions comprising one or more recombitope peptides. The invention further provides methods for designing recombitope peptides of the invention where the protein antigen to which the individual is sensitive has unknown or ill-defined T cell epitopes.Type: GrantFiled: June 16, 2003Date of Patent: May 1, 2007Assignee: Merck Patent GmbHInventors: Bruce L. Rogers, Jay P. Morgenstern, Julian F. Bond, Richard D. Garman, Julia L. Greenstein, Mei-Chang Kuo, Malcolm Morville
-
Patent number: 7166291Abstract: Isolated nucleic acids encoding allergens of Canis familiaris, Can fI or Can fII. are disclosed. A cDNA encoding a peptide having a Can fI activity and a predicted molecular weight of about 19,200 daltons is also described. A cDNA encoding a peptide having Can fII activity and a predicted molecular weight of about 18,200 daltons is also disclosed. The nucleic acids can be used as probes to detect the presence of Can fI or Can fII nucleic acid in a sample or for the recombinant production of petides having a Can fI or Can fII activity. Peptides having a Can fI or Can fII activity can be used in compositions suitable for pharmaceutical administration or methods of diagnosing sensitivity to dog dander.Type: GrantFiled: August 12, 2005Date of Patent: January 23, 2007Assignee: Heska CorporationInventors: Jay P. Morgenstern, Christine B. Bizinkauskas, Andrzej Konieczny, Andrew W. Brauer
-
Patent number: 7026128Abstract: Isolated nucleic acids encoding allergens of Canis familiaris, Can f I or Can f II, are disclosed. A cDNA encoding a peptide having a Can f I activity and a predicted molecular weight of about 19,200 daltons is also described. A cDNA encoding a peptide having Can f II activity and a predicted molecular weight of about 18,200 daltons is also disclosed. The nucleic acids can be used as probes to detect the presence of Can f I or Can f II nucleic acid in a sample or for the recombinant production of peptides having a Can f I or Can f II activity. Peptides having a Can f I or Can f II activity can be used in compositions suitable for pharmaceutical administration or methods of diagnosing sensitivity to dog dander.Type: GrantFiled: July 16, 2002Date of Patent: April 11, 2006Assignee: Heska CorporationInventors: Jay P. Morgenstern, Christine B. Bizinkauskas, Andrzej Konieczny, Andrew W. Brauer
-
Publication number: 20040057959Abstract: The present invention provides peptides having T cell stimulating activity termed recombitope peptides. Recombitope peptides of the invention preferably comprise at least two T cell epitopes derived from the same or from different protein antigens, and more preferably comprise at least two regions, each region preferably having human T cell stimulating activity and each region comprising at least one T cell epitope derived from a protein antigen. Recombitope peptides of the invention can be derived from protein allergens, autoantigens, or other protein antigens. The invention also provides methods of diagnosing sensitivity to a protein allergen or other protein antigen in an individual, methods to treat such sensitivity and therapeutic compositions comprising one or more recombitope peptides. The invention further provides methods for designing recombitope peptides of the invention where the protein antigen to which the individual is sensitive has unknown or ill-defined T cell epitopes.Type: ApplicationFiled: June 16, 2003Publication date: March 25, 2004Inventors: Bruce L. Rogers, Jay P. Morgenstern, Julian F. Bond, Richard D. Garman, Julia L. Greenstein, Mei-Chang Kuo, Malcolm Morville
-
Publication number: 20030049691Abstract: Isolated nucleic acids encoding allergens of Canis familiaris, Can f I or Can f II, are disclosed. A cDNA encoding a peptide having a Can f I activity and a predicted molecular weight of about 19,200 daltons is also described. A cDNA encoding a peptide having Can f II activity and a predicted molecular weight of about 18,200 daltons is also disclosed. The nucleic acids can be used as probes to detect the presence of Can f I or Can f II nucleic acid in a sample or for the recombinant production of peptides having a Can f I or Can f II activity. Peptides having a Can f I or Can f II activity can be used in compositions suitable for pharmaceutical administration or methods of diagnosing sensitivity to dog dander.Type: ApplicationFiled: July 16, 2002Publication date: March 13, 2003Inventors: Jay P. Morgenstern, Christine Bizinkauskas, Andrzej Konieczny, Andrew W. Brauer
-
Publication number: 20030035815Abstract: The present invention provides peptides having T cell stimulating activity termed recombitope peptides. Recombitope peptides of the invention preferably comprise at least two T cell epitopes derived from the same or from different protein antigens, and more preferably comprise at least two regions, each region preferably having human T cell stimulating activity and each region comprising at least one T cell epitope derived from a protein antigen. Recombitope peptides of the invention can be derived from protein allergens, autoantigens, or other protein antigens. The invention also provides methods of diagnosing sensitivity to a protein allergen or other protein antigen in an individual, methods to treat such sensitivity and therapeutic compositions comprising one or more recombitope peptides. The invention further provides methods for designing recombitope peptides of the invention where the protein antigen to which the individual is sensitive has unknown or ill-defined T cell epitopes.Type: ApplicationFiled: June 5, 1995Publication date: February 20, 2003Inventors: BRUCE L. ROGERS, JAY P. MORGENSTERN, JULIAN F. BOND, RICHARD D. GARMAN, JULIA L. GREENSTEIN, MEI-CHANG KUO, MALCOLM MORVILLE
-
Patent number: 6489118Abstract: Isolated nucleic acids encoding allergens of Canis familiaris, Canf I or Can f II, are disclosed. A cDNA encoding a peptide having a Can f I activity and a predicted molecular weight of about 19,200 daltons is also described. A cDNA encoding a peptide having Can f II activity and a predicted molecular weight of about 18,200 daltons is also disclosed. The nucleic acids can be used as probes to detect the presence of Can f I or Can f II nucleic acid in a sample or for the recombinant production of petides having a Can f I or Can f II activity. Peptides having a Can f I or Can f II activity can be used in compositions suitable for pharmaceutical administration or methods of diagnosing sensitivity to dog dander.Type: GrantFiled: August 16, 1999Date of Patent: December 3, 2002Assignee: ImmuLogic Pharmaceutical CorporationInventors: Jay P. Morgenstern, Christine B. Bizinkauskas, Andrzej Konieczny, Andrew W. Brauer
-
Publication number: 20020012963Abstract: Isolated nucleic acids encoding allergens of Canis familiaris, Canf I or Can f II, are disclosed. A cDNA encoding a peptide having a Can f I activity and a predicted molecular weight of about 19,200 daltons is also described. A cDNA encoding a peptide having Can f II activity and a predicted molecular weight of about 18,200 daltons is also disclosed. The nucleic acids can be used as probes to detect the presence of Can f I or Can f II nucleic acid in a sample or for the recombinant production of petides having a Can f I or Can f II activity. Peptides having a Can f I or Can f II activity can be used in compositions suitable for pharmaceutical administration or methods of diagnosing sensitivity to dog dander.Type: ApplicationFiled: August 16, 1999Publication date: January 31, 2002Applicant: ImmuLogic Pharmaceutical CorporationInventors: JAY P. MORGENSTERN, CHRISTINE B. BIZINKAUSKAS, ANDRZEJ KONIECZNY, ANDREW W. BRAUER
-
Patent number: 6048962Abstract: A substantially pure, covalently linked human T cell reactive feline protein (TRFP) has been isolated from vacuum bag extract obtained by affinity purification of house dust collected from several homes with cats; DNA encoding all or a portion of the TRFP or peptide; compositions containing such a protein or peptide or portions thereof; and antibodies reactive with the TRFP or peptide are disclosed. Also disclosed are recombinant TRFP or peptide; modified or mutated TRFP peptides; their use for diagnostic or therapeutic purposes.Type: GrantFiled: April 27, 1995Date of Patent: April 11, 2000Assignee: Immulogic Pharmaceutical CorporationInventors: Malcolm L. Gefter, Richard D. Garman, Julia L. Greenstein, Mei-chang Kuo, Bruce L. Rogers, Irwin J. Griffith, Jay P. Morgenstern, Andrew W. Brauer